Alzheimer's Association Names Zaven Khachaturian, Ph.D., Editor of Alzheimer's & Dementia
Chicago, Ill. – The Alzheimer's Association today announced that Zaven Khachaturian, Ph.D., will be the first editor of its new research journal, Alzheimer's & Dementia: The Journal of the Alzheimer's Association. The journal will debut at the Association's International Conference on Prevention of Dementia: Early Diagnosis and Intervention, June 18-21, 2005, at the Marriott Wardman Park Hotel in Washington, D.C.
Dr. Khachaturian has been a leading consultant, lecturer and author in the areas of brain aging, brain health and Alzheimer's disease for nearly five decades. Over that time, he has also served in many capacities to government or other non-profit organizations, including: former director at the Office of Alzheimer's Disease Research - National Institutes of Health (NIH); former associate director, Neuroscience and Neuropsychology of Aging Program (NNA) - National Institute on Aging (NIA); former director, the Alzheimer's Association's Nancy & Ronald Reagan Research Institute; and former member of the FDA Peripheral and Central Nervous System (PCNS) Advisory Committee. He now serves as vice chair of the board of directors of the National Capital Area Chapter of the Alzheimer's Association and as a senior medical and scientific advisor to the national office of the organization.
"For nearly 50 years, I have been working in the field of brain research. Being named editor of this new and exciting forum to investigate dementia and Alzheimer's is a great honor," said Dr. Khachaturian. "Research in the area of Alzheimer's disease and related disorders has experienced a tremendous expansion from clinical obscurity to prominence across a wide range of scientific, medical and social sciences. Alzheimer's & Dementia will add to the growing body of knowledge."
The mission of Alzheimer's & Dementia is to bridge the knowledge gaps across a wide range of bench-to-bedside investigations in the area of dementia and Alzheimer's disease. The journal will include comprehensive review articles; original research papers; information on clinical trials; short reports; abstracts of papers presented at international meetings; in-depth perspectives; and theoretical and/or translational papers that attempt to integrate knowledge across disciplines.
"The ultimate objective of Alzheimer's & Dementia is to create a new forum for researchers and clinicians to communicate and share ideas in the area of dementia and Alzheimer's," added Khachaturian.
Alzheimer's & Dementia will also feature peer-reviewed advances from every field involved in scientific research and clinical care of dementia. Other highlights will include reviews and expert perspectives from leaders in contributing disciplines, plus editorials and occasional special issues on topics of interest.
For information on subscribing or submitting manuscripts to Alzheimer's & Dementia, contact Elsevier Marketing Director Shannon Magee at 188.8.131.5212 or firstname.lastname@example.org
About the Alzheimer's Association
The Alzheimer's Association, the world leader in Alzheimer research and support, is the largest voluntary health organization dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer's. For nearly 25 years, the donor-supported, not-for-profit Alzheimer's Association has provided reliable information and care consultation; created supportive services for families; increased funding for dementia research; and influenced public policy changes.
The Alzheimer's Association's vision is a world without Alzheimer's and its dual mission is to eliminate Alzheimer's disease through the advancement of research and to enhance care and support for individuals, their families and caregivers. For more information, visit www.alz.org or call 1.800.272.3900.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in 74 offices worldwide publish more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect, MD Consult, Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
media line: 1.312.335.4078